Innovative Medicines Initiative (IMI)

See the following -

CDISC and TransCelerate Announce New Standard for Breast Cancer to Support Data Sharing for Oncology Research

Press Release | CDISC, TransCelerate BioPharma, Inc. | May 18, 2016

The need to rapidly and efficiently share new data in cancer research was recently, and powerfully, highlighted by U.S. Vice President Joe Biden as part of the Cancer Moonshot initiative. The Clinical Data Interchange Standards Consortium (CDISC) and TransCelerate BioPharma, Inc. (“TransCelerate”) announce today the open availability of a new CDISC Therapeutic Area (TA) Standard for Breast Cancer. The CDISC global TA standards can streamline the way clinical research is conducted so that data can be readily shared among clinicians, researchers and regulators around the world, thus leading to more rapid and “smarter” research...

Read More »

eTRIKS 'open source' EU project for sharing vital disease information

Colin Smith | Imperial College News | March 15, 2013

Developing a software system that enables pharmaceutical companies, governments, academia and hospitals to share information to advance our understanding of diseases is the focus of a major European Union funded project, which is led by researchers from Imperial College London. Read More »

Gathering a Health Care Industry Around an Open Source Solution: the Success of tranSMART

Andy Oram | EMR & EHR | May 18, 2015

The role of open source software in healthcare is relatively hidden and uncelebrated, but organizations such as the tranSMART Foundation prove that it is making headway behind the scenes. tranSMART won three awards at the recent Bio‐IT World conference, including Best in Show. The tranSMART Foundation is a non‐profit organization that develops creates software for translational research, performing tasks such as searching for patterns in genomes and how they are linked to clinical outcomes. Like most of the sustainable, highly successful open source projects, tranSMART avoids hiring programmers to do the work itself, but fosters a sense of community by coordinating more than 100 developers from the companies who benefit from the software.

Read More »

IMI—A New Path to New Medicines?

Jim Murray | OpenMedicine.EU | October 14, 2011

I spent an interesting morning last week in the European Parliament at a presentation of the Innovative Medicines Initiative. IMI is a joint undertaking between the European pharmaceutical association EFPIA and the EU to carry out projects, mostly in pre-competitive research, to help develop new and innovative medicines. Read More »

J&J, Roche And Others Back Tech Platform To Bolster Translational Drug Research

Ryan McBride | FierceBiotechIT | April 10, 2013

Pharma experts and academics have joined forces to support an existing platform for managing digital translational research data, and their efforts could boost the plodding pace of drug research. The tranSMART Foundation incorporated as a nonprofit last week to organize the open source effort, Roche's ($RHHBY) Michael Braxenthaler, who serves as co-CEO of the foundation, told FierceBiotech IT. Read More »

“Open Source” Drug Discovery - €196M Program Launched

Ben Steele | eyeforpharma | February 8, 2013

Major pharma firms have joined together in a consortium with academics and SMEs that will invest €196 million in a new project to give a boost to ‘open-source’ drug discovery in the EU. Read More »